{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:43:16Z","timestamp":1793889796769,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","award":["88668477"],"award-info":[{"award-number":["88668477"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rimegepant, a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is indicated for acute and preventive migraine treatment in the United States and other countries. However, there is a lack of prospective real-world evidence for the use of rimegepant in Chinese migraine patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a single-arm, prospective, real-world study. While taking rimegepant to treat migraine attacks as needed, eligible participants were asked to record their pain intensity, functional ability, and accompanying symptoms for a single attack at predose and 0.5, 1, 2, 24, and 48\u00a0h postdose via a digital platform. Adverse events (AEs) during the rimegepant treatment period were recorded and analysed. The percentages of participants who experienced moderate to severe pain at predose and 0.5, 1, 2, 24, and 48\u00a0h postdose were assessed. Additionally, the percentages of participants who reported better\/good outcomes in terms of pain intensity, functional ability, and accompanying symptoms at 0.5, 1, 2, 24, and 48\u00a0h postdose were analysed. In addition, the total cohort (full population, FP) was stratified into a prior nonresponder (PNR) group to observe the effectiveness and safety of rimegepant for relatively refractory migraine and a rimegepant and eptinezumab (RE) group to observe the effectiveness and safety of the combination of these drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>By November 24th, 2023, 133 participants (FP, <jats:italic>n<\/jats:italic>\u2009=\u2009133; PNR group, <jats:italic>n<\/jats:italic>\u2009=\u200940; RE group, <jats:italic>n<\/jats:italic>\u2009=\u200928) were enrolled, and 99 participants (FP, <jats:italic>n<\/jats:italic>\u2009=\u200999; PNR group, <jats:italic>n<\/jats:italic>\u2009=\u200930; RE group, <jats:italic>n<\/jats:italic>\u2009=\u200923) were included in the analysis. Rimegepant was effective in treating migraine in the FP and both subgroups, with a significant decreasing trend in the percentages of participants experiencing moderate to severe pain postdose (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and a marked increase in the percentages of participants who reported better\/good outcomes in terms of pain intensity, functional ability, and accompanying symptoms at 0.5, 1, 2, 24, and 48\u00a0h postdose compared with predose. AEs were reported by 6% of participants in the FP, and all AEs were mild.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In the real world, rimegepant is effective in the acute treatment of migraine patients in China. The low incidence rate of AEs highlighted the favourable tolerability profile of rimegepant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinicaltrials.gov NCT05709106. Retrospectively registered on 2023-02-01.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01873-5","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:02:43Z","timestamp":1727449363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyue","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhou","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"1873_CR1","doi-asserted-by":"publisher","first-page":"e2141","DOI":"10.1212\/WNL.0000000000207218","volume":"100","author":"Y Wang","year":"2023","unstructured":"Wang Y, Liang J, Fang Y et al (2023) Burden of common neurologic diseases in Asian countries, 1990\u20132019: an analysis for the global burden of Disease Study 2019. Neurology 100:e2141\u2013e2154","journal-title":"Neurology"},{"key":"1873_CR2","unstructured":"(2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211"},{"key":"1873_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-024-01731-4","volume":"25","author":"S Yu","year":"2024","unstructured":"Yu S, Guo A, Wang Z et al (2024) Rimegepant orally disintegrating tablet 75\u00a0mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial. J Headache Pain 25:57","journal-title":"J Headache Pain"},{"key":"1873_CR4","first-page":"197","volume":"29","author":"RE Shapiro","year":"2023","unstructured":"Shapiro RE, Martin AA, Bhardwaj S et al (2023) Relationships between headache frequency, disability, and disability-related unemployment among adults with migraine. J Manag Care Spec Pharm 29:197\u2013209","journal-title":"J Manag Care Spec Pharm"},{"key":"1873_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R et al (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137","journal-title":"J Headache Pain"},{"key":"1873_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society (2021) The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039","journal-title":"Headache"},{"key":"1873_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/ene.15103","volume":"29","author":"HC Diener","year":"2022","unstructured":"Diener HC, Gaul C, Lehmacher W, Weiser T (2022) Aspirin, Paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: a systemic review and meta-analysis of randomized placebo-controlled trials. Eur J Neurol 29:350\u2013357","journal-title":"Eur J Neurol"},{"key":"1873_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40263-023-00988-8","volume":"37","author":"HA Blair","year":"2023","unstructured":"Blair HA (2023) Rimegepant: a review in the Acute Treatment and Preventive Treatment of Migraine. CNS Drugs 37:255\u2013265","journal-title":"CNS Drugs"},{"key":"1873_CR9","doi-asserted-by":"publisher","first-page":"215013272096368","DOI":"10.1177\/2150132720963680","volume":"11","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Shewale AS, Lipton RB et al (2020) Migraine patients with Cardiovascular Disease and contraindications: an analysis of real-world Claims Data. J Prim Care Community Health 11:2150132720963680","journal-title":"J Prim Care Community Health"},{"key":"1873_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","volume":"9","author":"S Ashina","year":"2023","unstructured":"Ashina S, Terwindt GM, Steiner TJ et al (2023) Medication overuse headache. Nat Rev Dis Primers 9:5","journal-title":"Nat Rev Dis Primers"},{"key":"1873_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM et al (2022) European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 23:133","journal-title":"J Headache Pain"},{"key":"1873_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40265-020-01301-3","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ (2020) Rimegepant: first approval. Drugs 80:741\u2013746","journal-title":"Drugs"},{"key":"1873_CR13","unstructured":"The State Council Information Office of the People\u2019s Republic of China (2024) Notice by the People\u2019s Government of Hainan Province regarding the Temporary Provisions of Regulations on Clinically Urgently Needed Imported Drugs in the International Medical Tourism Pilot Zone in Hainan Boao Lecheng. http:\/\/www.scio.gov.cn\/xwfb\/gwyxwbgsxwfbh\/wqfbh_2284\/2019n_5801\/2019n09y16rxw2\/wjxgzc_6808\/202207\/t20220715_217314.html. Accessed 3 March 2024"},{"key":"1873_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG et al (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for Migraine. N Engl J Med 381:142\u2013149","journal-title":"N Engl J Med"},{"key":"1873_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394:737\u2013745","journal-title":"Lancet"},{"key":"1873_CR16","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2147\/JPR.S453806","volume":"17","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Thiry A, Morris BA, Croop R (2024) Efficacy and safety of Rimegepant 75\u00a0mg oral tablet, a CGRP receptor antagonist, for the Acute treatment of migraine: a Randomized, Double-Blind, placebo-controlled trial. J Pain Res 17:2431\u20132441","journal-title":"J Pain Res"},{"key":"1873_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397:51\u201360","journal-title":"Lancet"},{"key":"1873_CR18","doi-asserted-by":"publisher","first-page":"033310242412329","DOI":"10.1177\/03331024241232944","volume":"44","author":"R Croop","year":"2024","unstructured":"Croop R, Berman G, Kudrow D et al (2024) A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia 44:03331024241232944","journal-title":"Cephalalgia"},{"key":"1873_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1474-4422(23)00126-6","volume":"22","author":"S Yu","year":"2023","unstructured":"Yu S, Kim B-K, Guo A et al (2023) Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 22:476\u2013484","journal-title":"Lancet Neurol"},{"key":"1873_CR20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40122-023-00494-1","volume":"12","author":"L Zhang","year":"2023","unstructured":"Zhang L, Novick D, Zhong S et al (2023) Real-world analysis of clinical characteristics, treatment patterns, and patient-reported outcomes of Insufficient responders and responders to prescribed Acute Migraine Treatment in China. Pain Ther 12:751\u2013769","journal-title":"Pain Ther"},{"key":"1873_CR21","doi-asserted-by":"publisher","first-page":"1263535","DOI":"10.3389\/fneur.2023.1263535","volume":"14","author":"J Robblee","year":"2023","unstructured":"Robblee J (2023) Breaking the cycle: unraveling the diagnostic, pathophysiological and treatment challenges of refractory migraine. Front Neurol 14:1263535","journal-title":"Front Neurol"},{"key":"1873_CR22","doi-asserted-by":"publisher","first-page":"333102422114168","DOI":"10.1177\/03331024221141686","volume":"43","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Blumenfeld A, Jensen CM et al (2023) Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: pooled results from three phase 3 randomized clinical trials. Cephalalgia 43:3331024221141686","journal-title":"Cephalalgia"},{"key":"1873_CR23","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/head.13930","volume":"60","author":"G Berman","year":"2020","unstructured":"Berman G, Croop R, Kudrow D et al (2020) Safety of Rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for Migraine. Headache 60:1734\u20131742","journal-title":"Headache"},{"key":"1873_CR24","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1212\/WNL.0000000000008944","volume":"94","author":"K Mullin","year":"2020","unstructured":"Mullin K, Kudrow D, Croop R et al (2020) Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 94:e2121\u2013e2125","journal-title":"Neurology"},{"key":"1873_CR25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350","journal-title":"Nat Rev Neurol"},{"key":"1873_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/bs.pbr.2020.06.019","volume":"255","author":"C-C Chiang","year":"2020","unstructured":"Chiang C-C, Schwedt TJ (2020) Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-the monoclonal antibodies and gepants. Prog Brain Res 255:143\u2013170","journal-title":"Prog Brain Res"},{"key":"1873_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s11136-012-0230-7","volume":"22","author":"R Rendas-Baum","year":"2013","unstructured":"Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF (2013) The psychometric properties of the migraine-specific quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients. Qual Life Res 22:1123\u20131133","journal-title":"Qual Life Res"},{"key":"1873_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963\u2013974","journal-title":"Qual Life Res"},{"key":"1873_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-022-01461-5","volume":"23","author":"Y Ran","year":"2022","unstructured":"Ran Y, Yin Z, Lian Y et al (2022) Gradually shifting clinical phenomics in migraine spectrum: a cross-sectional, multicenter study of 5438 patients. J Headache Pain 23:89","journal-title":"J Headache Pain"},{"key":"1873_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s10194-023-01654-6","volume":"24","author":"H Liu","year":"2023","unstructured":"Liu H, Dong M, Liu K et al (2023) Status of diagnosis and preventative treatment for primary headache disorders: real-world data of unmet needs in China. J Headache Pain 24:119","journal-title":"J Headache Pain"},{"key":"1873_CR31","unstructured":"National Medical Products Administration (2024) Import medicine product -National drug standard HJ20240004 basic information. https:\/\/www.nmpa.gov.cn\/datasearch\/search-info.html?nmpa=aWQ9YzMwYTM3MzI4YTdiOTBkZGFlYzY4MDc1ZDllODE4MTkmaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4NjY1NzExODAw. Accessed 29 Jul 2024"},{"key":"1873_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-023-01622-0","volume":"24","author":"A Manack Adams","year":"2023","unstructured":"Manack Adams A, Hutchinson S, Engstrom E et al (2023) Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE study. J Headache Pain 24:102","journal-title":"J Headache Pain"},{"key":"1873_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1177\/0333102420983282","volume":"41","author":"M Bhakta","year":"2021","unstructured":"Bhakta M, Vuong T, Taura T et al (2021) Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia 41:499\u2013514","journal-title":"Cephalalgia"},{"key":"1873_CR34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/14737175.2020.1772758","volume":"20","author":"E De Matteis","year":"2020","unstructured":"De Matteis E, Guglielmetti M, Ornello R et al (2020) Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother 20:627\u2013641","journal-title":"Expert Rev Neurother"},{"key":"1873_CR35","unstructured":"Medical physician branch of the Chinese physicians association Chinese research hospitals learn headaches and sensory disorders professional committees (2022) Chinese migraine diagnosis and treatment guidelines (2022). Chin J Pain Med 2022:881\u2013898"},{"key":"1873_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-021-01378-5","volume":"23","author":"K Johnston","year":"2022","unstructured":"Johnston K, Harris L, Powell L et al (2022) Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201). J Headache Pain 23:10","journal-title":"J Headache Pain"},{"key":"1873_CR37","unstructured":"Yu S, Zhong Q, Zhu H et al (2023) Exposure, Safety and Effectiveness of 75\u00a0mg Rimegepant Administered as Needed in the Acute Treatment of Migraine Among Chinese Adults: Interim Subgroup Analysis of a Long-term Safety Study. Poster presented at the 17th European Headache Congress (EHC), Barcelona, Spain, 6\u20139 December 2023"},{"key":"1873_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-019-1062-4","volume":"20","author":"T Takeshima","year":"2019","unstructured":"Takeshima T, Wan Q, Zhang Y et al (2019) Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain 20:111","journal-title":"J Headache Pain"},{"key":"1873_CR39","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s40122-021-00273-w","volume":"10","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Orologio I, Bonavita S et al (2021) Effectiveness and safety of CGRP-mAbs in menstrual-related migraine: a real-world experience. Pain Ther 10:1203\u20131214","journal-title":"Pain Ther"},{"key":"1873_CR40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/0333102411433042","volume":"32","author":"M Lant\u00e9ri-Minet","year":"2012","unstructured":"Lant\u00e9ri-Minet M, Mick G, Allaf B (2012) Early dosing and efficacy of triptans in acute migraine treatment: the TEMPO study. Cephalalgia 32:226\u2013235","journal-title":"Cephalalgia"},{"key":"1873_CR41","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1468-2982.2008.01546.x","volume":"28","author":"PJ Goadsby","year":"2008","unstructured":"Goadsby PJ, Zanchin G, Geraud G et al (2008) Early vs. non-early intervention in acute migraine-\u2019act when mild (AwM)\u2019. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 28:383\u2013339","journal-title":"Cephalalgia"},{"key":"1873_CR42","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1185\/030079904X2745","volume":"20","author":"R Cady","year":"2004","unstructured":"Cady R, Elkind A, Goldstein J, Keywood C (2004) Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin 20:1465\u20131472","journal-title":"Curr Med Res Opin"},{"key":"1873_CR43","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/S0140-6736(23)01683-5","volume":"402","author":"DW Dodick","year":"2023","unstructured":"Dodick DW, Goadsby PJ, Schwedt TJ et al (2023) Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet 402:2307\u20132316","journal-title":"Lancet"},{"key":"1873_CR44","doi-asserted-by":"publisher","first-page":"333102424124565","DOI":"10.1177\/03331024241245658","volume":"44","author":"W Rattanawong","year":"2024","unstructured":"Rattanawong W, Rapoport A, Srikiatkhachorn A (2024) Medication underuse headache. Cephalalgia 44:3331024241245658","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01873-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01873-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01873-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T03:46:03Z","timestamp":1727495163000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01873-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1873"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01873-5","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent before enrolment. The participants were informed that their personal deidentified study-related data would be used in accordance with local privacy and data protection laws. The study protocol was approved by the Institutional Ethics Committees of Ruijin Hospital-Shanghai Jiao Tong University School of Medicine in China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}